Ultrastructural analysis of colonies growing in a human tumor cloning system

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Cancer chemotherapy and pharmacology·2014

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

European journal of cancer (Oxford, England : 1990)·2012

Telomerase and telomere inhibitors in preclinical development.

Expert opinion on investigational drugs·2005

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

Cancer·2026

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.

Cancer·2026

The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023.

Cancer·2026

Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion.

Cancer·2026

Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026.

Cancer·2026

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

Cancer·2026

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

Blood·2026

Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis: A Propensity-Matched Analysis.

Clinical spine surgery·2026

Squamous Cell Carcinoma Developing from an Epidermal Inclusion Cyst on the Buttock.

Plastic and reconstructive surgery. Global open·2026

Jejunal Mixed Adenoneuroendocrine Carcinoma (MANEC) With a Novel PTPRK-RSPO3 Fusion Initially Presenting as a Large Ovarian Mass: Diagnostic Challenges and Poor Prognosis.

Cancer diagnosis & prognosis·2026

Management of Tibial Adamantinoma: Balancing Oncologic Cure and Reconstructive Longevity.

Cureus·2026

Risk-Stratified Bilateral Tonsillectomy for Unilateral HPV-Associated Tonsillar SCC: Oncologic and Functional Outcomes From a Single Institution.

Laryngoscope investigative otolaryngology·2026

Related Experiment Videos

Ultrastructural analysis of colonies growing in a human tumor cloning system

Related Concept Videos

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

Telomerase and telomere inhibitors in preclinical development.

GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies.

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection.

The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023.

Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion.

Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026.

Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

Investigating the Relationship Between Glucagon-Like Peptide-1 Receptor Agonist Use and Incidence of Vertebral Fractures in Female Patients Aged Over 50 Years With Osteoporosis: A Propensity-Matched Analysis.

Squamous Cell Carcinoma Developing from an Epidermal Inclusion Cyst on the Buttock.

Jejunal Mixed Adenoneuroendocrine Carcinoma (MANEC) With a Novel PTPRK-RSPO3 Fusion Initially Presenting as a Large Ovarian Mass: Diagnostic Challenges and Poor Prognosis.

Management of Tibial Adamantinoma: Balancing Oncologic Cure and Reconstructive Longevity.

Risk-Stratified Bilateral Tonsillectomy for Unilateral HPV-Associated Tonsillar SCC: Oncologic and Functional Outcomes From a Single Institution.

Related Experiment Videos

Ultrastructural analysis of colonies growing in a human tumor cloning system

Related Concept Videos

Related Articles